We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

By LabMedica International staff writers
Posted on 04 Feb 2026

Alzheimer’s disease affects approximately 6. More...

7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests that imbalances in the gut microbiome—known as dysbiosis—may contribute to the onset and progression of mild cognitive impairment (MCI) and Alzheimer’s disease.

Researchers are increasingly focused on the microbiota–gut–brain axis, a complex network linking the gut, immune system, and brain. Disruptions in this system are thought to promote neuroinflammation, leading to damage of nerve cells and potentially accelerating cognitive decline associated with Alzheimer’s disease. New research has revealed reproducible bacterial and functional signatures linking gut microbiome dysbiosis to MCI and Alzheimer’s disease.

George Washington University (Washington, DC, USA) researchers analyzed 58 human studies published through February 2023, constituting the most comprehensive human-only review in this area. Published January 22, 2026 in Alzheimer’s & Dementia, the work assessed microbiome composition, diversity, and predicted function. 

Across multiple studies, people with mild cognitive impairment and Alzheimer’s disease consistently exhibited gut microbiota profiles that differed from those of cognitively healthy older adults. Alzheimer’s disease was associated with higher levels of certain bacterial groups, particularly the phyla Pseudomonadota and Actinomycetota. In addition, some individuals with Alzheimer’s disease showed reduced gut microbial diversity, meaning they had fewer types of bacteria than typically observed.

The types and relative abundance of gut bacteria differ among people with MCI, Alzheimer’s disease, and cognitively healthy individuals, suggesting distinct microbiome signatures at different stages of cognitive decline. In people with Alzheimer’s disease, functional alterations in gut bacteria have also been observed, including reduced activity in pathways related to energy production and immune function.

Although the review does not establish a cause-and-effect relationship, its findings are consistent with broader evidence indicating that diets high in fiber may promote a healthier gut microbiome, with possible downstream benefits for inflammation and brain health.

“While these early, largely observational results are encouraging, we need clinical trials to determine whether microbiome-targeted interventions can meaningfully alter disease trajectories. These trials are already underway in our lab and labs around the world.” said lead researcher Leigh Frame, associate professor in the George Washington University School of Medicine and Health Sciences. 

Related Links
GW School of Medicine & Health Science


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.